Prediction of Incident Heart Failure in TTR Val122Ile Carriers One Year Ahead of Diagnosis in a Multiethnic Biobank

Kumardeep Chaudhary; Ben O. Petrazzini; Jagat Narula; Girish N. Nadkarni; Ron Do

doi:10.1016/j.amjcard.2020.12.015

Prediction of Incident Heart Failure in TTR Val122Ile Carriers One Year Ahead of Diagnosis in a Multiethnic Biobank

Kumardeep Chaudhary
, Ben O. Petrazzini
, Jagat Narula
, Girish N. Nadkarni
, Ron Do

Research output: Contribution to journal › Letter › peer-review

3 Scopus citations

Original language	English
Pages (from-to)	151-153
Number of pages	3
Journal	American Journal of Cardiology
Volume	142
DOIs	https://doi.org/10.1016/j.amjcard.2020.12.015
State	Published - 1 Mar 2021

Access to Document

10.1016/j.amjcard.2020.12.015

Cite this

@article{e7e68c379d914472b5ec6b241a9c4c02,

title = "Prediction of Incident Heart Failure in TTR Val122Ile Carriers One Year Ahead of Diagnosis in a Multiethnic Biobank",

author = "Kumardeep Chaudhary and Petrazzini, \{Ben O.\} and Jagat Narula and Nadkarni, \{Girish N.\} and Ron Do",

note = "Funding Information: Dr Do is supported by the National Institute of General Medical Sciences of the National Institutes of Health ( NIH ) ( R35-GM124836 ) and the National Heart, Lung, and Blood Institute of the NIH ( R01-HL139865 ). Dr Nadkarni is supported by a career development award from the NIH ( K23-DK107908 ) and by NIH grants R01-DK108803 , U01-HG007278 , U01-HG009610 , and U01-DK116100 . Funding Information: Dr Do reported receiving grants from AstraZeneca, grants and nonfinancial support from Goldfinch Bio, being a scientific co-founder and equity holder for Pensieve Health and being a consultant for Variant Bio. Dr Nadkarni reported being a scientific co-founder, consultant, advisory board member, and equity owner of Renalytix AI, is a scientific co-founder and equity holder for Pensieve Health, being a consultant for Variant Bio and receiving grants from Goldfinch Bio and receiving personal fees from Renalytix AI, BioVie, Reata, AstraZeneca and GLG Consulting. No other disclosures were reported. ",

year = "2021",

month = mar,

day = "1",

doi = "10.1016/j.amjcard.2020.12.015",

language = "English",

volume = "142",

pages = "151--153",

journal = "American Journal of Cardiology",

issn = "0002-9149",

publisher = "Elsevier Inc.",

}

TY - JOUR

T1 - Prediction of Incident Heart Failure in TTR Val122Ile Carriers One Year Ahead of Diagnosis in a Multiethnic Biobank

AU - Chaudhary, Kumardeep

AU - Petrazzini, Ben O.

AU - Narula, Jagat

AU - Nadkarni, Girish N.

AU - Do, Ron

N1 - Funding Information: Dr Do is supported by the National Institute of General Medical Sciences of the National Institutes of Health ( NIH ) ( R35-GM124836 ) and the National Heart, Lung, and Blood Institute of the NIH ( R01-HL139865 ). Dr Nadkarni is supported by a career development award from the NIH ( K23-DK107908 ) and by NIH grants R01-DK108803 , U01-HG007278 , U01-HG009610 , and U01-DK116100 . Funding Information: Dr Do reported receiving grants from AstraZeneca, grants and nonfinancial support from Goldfinch Bio, being a scientific co-founder and equity holder for Pensieve Health and being a consultant for Variant Bio. Dr Nadkarni reported being a scientific co-founder, consultant, advisory board member, and equity owner of Renalytix AI, is a scientific co-founder and equity holder for Pensieve Health, being a consultant for Variant Bio and receiving grants from Goldfinch Bio and receiving personal fees from Renalytix AI, BioVie, Reata, AstraZeneca and GLG Consulting. No other disclosures were reported.

PY - 2021/3/1

Y1 - 2021/3/1

UR - https://www.scopus.com/pages/publications/85099117312

U2 - 10.1016/j.amjcard.2020.12.015

DO - 10.1016/j.amjcard.2020.12.015

M3 - Letter

C2 - 33333072

AN - SCOPUS:85099117312

SN - 0002-9149

VL - 142

SP - 151

EP - 153

JO - American Journal of Cardiology

JF - American Journal of Cardiology

ER -